Regulatory T cells points towards organ transplants free of immunosuppressents

A recent review from Japan has outlined how regulatory T cell therapies, including chimeric antigen receptor-engineered and gene-edited universal cell products, could help to induce donor-specific immune tolerance and reduce long-term dependence on broad-spectrum immunosuppression after solid organ transplantation

Organ transplantation has remained the cornerstone treatment for patients with end-stage organ failure but the need for long-term immunosuppression has continued to limit clinical outcomes. Conventional broad-spectrum immunosuppressive drugs can control acute rejection but they do not adequately resolve chronic rejection and can expose patients to serious long-term complications, including infection, malignancy and metabolic disorders.

Against this background, donor-specific immune tolerance has become a central aim in transplant immunology. Rather than suppress the immune system as a whole, researchers have sought to direct immune regulation towards the transplanted organ while preserving wider immune defence. A comprehensive review from Professor Xiao-Kang Li’s team from the division of transplantation immunology, National Research Institute for Child Health and Development, Tokyo, Japan, has examined how regulatory T cells (Tregs) could provide the biological and technological basis for this shift.

Tregs are recognised as key arbiters of immune homeostasis within the transplant immune network. The review described them not as agents of a single suppressive pathway but as cells that deploy a coordinated set of mechanisms to protect grafts from immune-mediated injury. These mechanisms include the secretion of inhibitory cytokines, such as interleukin-10 and transforming growth factor beta, the induction of effector T cell apoptosis and the modulation of dendritic cell activity. Through these actions, Tregs can help to establish durable immune tolerance both at the graft site and systemically.

The authors said these universal mechanisms have provided a common biological framework for solid organ transplantation, including liver, kidney and heart transplantation. Because each transplanted organ presents a distinct immune microenvironment, a detailed understanding of both shared and organ-specific mechanisms will be required to translate Treg biology into effective treatment. The review argued that these principles form the first step towards precise immune modulation in transplantation.

The field has moved from conventional cell expansion towards increasingly sophisticated engineering strategies. Early work focused on polyclonal Tregs, in which autologous Tregs were isolated from the patient and expanded outside the body before reinfusion. This approach helped to establish an initial safety profile but it faced practical and biological limitations, including variable expansion efficiency and insufficient graft specificity.

The next stage has involved chimeric antigen receptor-engineered Tregs – or CAR-Tregs. By equipping Tregs with chimeric antigen receptors, researchers have given them a targeted recognition system that can direct their suppressive activity towards specific graft antigens. This approach could allow more potent local immunoregulation at the transplant site while reducing the need for generalised immune suppression.

The review also highlighted the development of universal, off-the-shelf Treg products as a major recent step in the field. Gene-editing tools such as clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9) have been used to create hypoimmunogenic Tregs. By altering or removing human leukocyte antigen molecules, engineered Tregs may evade immune recognition by the recipient and become suitable for standardised, scalable manufacture.

This development could move transplant medicine beyond highly personalised, labour-intensive cell preparation and towards more accessible cellular drug products. The authors suggested that such progress could help to transform Treg therapy from an experimental concept into a practical translational strategy for solid organ transplantation.

“Future breakthroughs in transplant immunology depend on integrating universal technology platforms – such as universal CAR-Tregs – with a deep understanding of organ-specific immune microenvironments,” the authors said.

By combining the antigen-targeted function of chimeric antigen receptors, the practical convenience of off-the-shelf cell products and the biological potency of synergistic immune regulation, Treg therapy could become a tailored strategy to induce stable immune tolerance across a wide range of transplant settings. The review framed this shift as a move from passive immunosuppression towards active tolerance induction, with the long-term goal of transplantation that requires little or no conventional immunosuppressant therapy.

The authors concluded that the convergence of gene editing, cell engineering and precision immune regulation could mark a decisive turning point for transplant medicine. The review has provided both a theoretical framework and a translational pathway for efforts to improve long-term graft survival and reduce treatment-related harm after solid organ transplantation.0

“As gene editing, cell engineering, and precision immune regulation technologies become increasingly integrated, Treg cell therapy is poised to become a landmark breakthrough in transplant medicine, ultimately realising the ideal state of low- or zero-immunosuppressant dependency,” the authors added.

For further reading please visit: 10.1007/s44466-026-00037-1